Quantum Computing Inc. (QUBT) is positioning itself as a vertically integrated quantum optics and integrated photonics company, pairing quantum machines with TFLN foundry services and advanced semiconductor packaging. Its products are designed to operate at room temperature and low power — a meaningful differentiation against superconducting, ion-trap, and annealing architectures that typically require extreme cooling and costly infrastructure.
The company's market positioning has shifted decisively in 2026. Through the acquisition of Luminar Semiconductor (lasers, detectors, and packaging), NuCrypt (quantum communications), and NHanced Semiconductors (hybrid bonding and chiplet architectures), QUBT now spans photonic components, subsystems, and full-stack systems. This broadens its addressable market beyond quantum computing into AI networking, defense, aerospace, telecommunications, and remote sensing. The Fab 2 initiative, accelerated by the NHanced acquisition, is intended to move the company from small-batch prototyping toward higher-volume manufacturing — a transition management has framed as moving from a technology-innovation firm to a scale-up manufacturer.
Structural risks remain. Revenue is heavily concentrated in government and aerospace subcontracts (roughly 70% of backlog), gross margins are still in the low single digits, and the company offers no formal guidance because of the lumpy timing of orders. Execution on manufacturing utilization and margin improvement will be the primary determinants of medium-term competitive standing. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Several developments could shape investor sentiment over the coming quarters. The first customer shipment of the Dirac-3S optimization machine, expected in the fourth quarter of 2026, is a pivotal proof point — management has cited benchmark results that compare favorably against leading classical solvers, and the product supports both cloud and on-premise deployments. The company's first pharmaceutical customer (INmune Bio) and an international academic user (Hamad Bin Khalifa University in Qatar) suggest early commercial diversification beyond government contracts.
Manufacturing execution is another key catalyst. Fab 2 capital expenditures are estimated at $70–80 million, with spending expected to extend through roughly mid-2027. Successful utilization gains could lift gross margins toward the 20–30% level management has described as achievable with volume, directly addressing the profitability gap. The strategic collaboration with POET Technologies to develop TFLN-based 3.2-terabit-per-second optical engines for AI networks also positions QUBT in a high-growth interconnect market.
On the analyst front, consensus remains constructive but wide-ranging. As of late 2026, the average 12-month price target sits near $18–19, with a high of $32 (Ascendiant) and a low of $10 (Cantor Fitzgerald). Coverage includes Buy ratings from Ascendiant, Rosenblatt, Lake Street, Northland, and Titan Partners, alongside Neutral ratings from Cantor Fitzgerald and Wedbush. Target revisions have generally trended upward through 2026, reflecting cautious optimism about the company's expanded manufacturing footprint, even as margin concerns temper enthusiasm.
QUBT's future outlook is closely tied to several macro and industry forces. Federal defense and aerospace budgets — a primary revenue source — are sensitive to political cycles and post-election funding uncertainty. Interest-rate policy also matters: as a high-beta, cash-rich but unprofitable technology company, QUBT's valuation is vulnerable to shifts in investor risk appetite driven by monetary conditions. Notably, the company's sizable cash and investment balances generate meaningful interest income that currently cushions reported losses, so any decline in rates could narrow that buffer.
On the demand side, accelerating adoption of AI is driving investment in high-bandwidth optical interconnects, a market QUBT's TFLN photonics directly targets. Quantum-adjacent themes — cybersecurity, sensing, and optimization — are gaining enterprise and government traction, though commercialization timelines remain uncertain. Regulatory dynamics cut both ways: potential export-control restrictions (such as ITAR, or International Traffic in Arms Regulations) limit international expansion, while U.S. government emphasis on domestic semiconductor and photonics manufacturing could favor QUBT's onshore foundry strategy.
Heading into 2027, QUBT's trajectory hinges on its ability to convert a strengthened manufacturing base into sustained, higher-margin revenue. The $39.1 million backlog — mostly government and aerospace — provides near-term visibility, but management expects the mix to balance toward commercial customers over time as technologies mature. Long-term themes to monitor include the ramp of Fab 2 capacity, integration of the acquired photonics and packaging businesses, and the company's migration toward TFLN-based integrated circuits that could reduce costs and improve scalability.
Margin sustainability is the central watch item. Current gross margins near 4.5% must expand substantially for the business model to become self-sustaining, and rising operating expenses — headcount now exceeds 330 — will pressure the income statement in the interim. Capital allocation will also be scrutinized: the company has signaled continued appetite for mergers and acquisitions (M&A), and each acquisition or capital-expenditure dollar reduces the interest income currently supporting results.
Competitively, QUBT faces both established quantum rivals and specialized classical solvers, while export controls constrain international reach. Consensus analyst expectations reflect this tension — constructive on the technology and balance sheet, cautious on execution. The company's forward path will ultimately be defined by whether its photonics foundry strategy can deliver the volume and margin trajectory that its stock forecast currently anticipates.
When analyzing names like QUBT, I often turn to Tickeron’s AI Trend Prediction Engine to get an additional data-driven perspective on potential directional moves. It surfaces developing trends and helps evaluate possible breakouts or reversals across a wide range of assets. I have found it useful for cross-checking fundamental views with quantitative signals, especially for volatile, catalyst-driven stocks where timing can matter.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
On November 06, 2026, the Stochastic Oscillator for QUBT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 64 instances where the indicator left the oversold zone. In 59 of the 64 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where QUBT's RSI Indicator exited the oversold zone, 23 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for QUBT just turned positive on November 09, 2026. Looking at past instances where QUBT's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.
Following a +21.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where QUBT advanced for three days, in 193 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
QUBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QUBT as a result. In 70 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The 10-day moving average for QUBT crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QUBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for QUBT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.900) is normal, around the industry mean (-6.197). QUBT's P/E Ratio (-158.250) is considerably lower than the industry average of (-3.670). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (23.994). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (169.492) is also within normal values, averaging (51.774).
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. QUBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QUBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry ComputerProcessingHardware